Vynleads, Inc. Annual Report: A Plain-English Summary

I’ve put together this guide to help you understand how Vynleads performed this year. My goal is to cut through the corporate jargon so you can decide if this company belongs in your portfolio.

1. What does this company do?

Vynleads has pivoted from selling physical supplements to becoming a software company focused on wellness. Their core product, the "DWX" platform, uses AI to act as a digital health coach by tracking health markers and providing real-time nutritional advice. They are currently developing "agentic" AI to automate meal planning and glucose tracking, with the goal of selling this software to companies and health insurers as a preventative health tool.

2. Financial performance: The "Zero Revenue" Reality

This is the most important point: The company generated $0 in sales for the year ending December 31, 2025.

Despite having no revenue, the company incurred $247,000 in expenses, including $115,000 in legal fees, $82,000 for consultants, and $50,000 for overhead. This resulted in a net loss of $255,000 for the year. Since its inception, Vynleads has accumulated losses of approximately $3.1 million. As of December 31, 2025, the company held only $12,400 in cash and is currently relying on $185,000 in loans from company-affiliated individuals. Management estimates they require at least $500,000 in immediate funding to support development and sales operations for the coming year.

3. Major wins and challenges

The company’s strategy centers on the DWX platform, with plans to launch pilot programs for mid-sized companies to demonstrate potential insurance cost savings. However, the sales cycle for large corporate clients is lengthy, typically ranging from 9 to 18 months. Furthermore, the company maintains a very lean structure; as of March 2026, the CEO is the only full-time employee, with all engineering and sales functions handled by outside contractors.

4. Key risks

• Operational Dependency: The business relies entirely on the CEO. The loss of this individual or the departure of key contractors would likely result in an immediate cessation of operations.
• AI Reliability: The AI platform may provide inaccurate information. Inaccurate health advice poses a significant risk of litigation.
• Regulatory Hurdles: The company operates in a legal gray area. A determination by the FDA that their software qualifies as a medical device would necessitate years of expensive clinical trials.
• Legal Baggage: An ongoing 2017 dispute regarding book royalties continues to drain cash, with approximately $45,000 in potential costs remaining.
• Data Security: Handling private health data carries inherent risks; a data breach could lead to substantial federal fines and irreparable damage to the company’s reputation with corporate clients.

5. Future outlook

Vynleads is fully committed to an AI-driven health model. Their survival is contingent upon securing an investor or strategic partner within the next six months. The company’s auditor has issued a warning regarding their ability to continue as a going concern. Without a rapid transition to revenue generation, the company faces a high risk of insolvency.

Investor Takeaway: Vynleads is currently a high-risk, pre-revenue startup. When evaluating this opportunity, consider whether you are comfortable with a company that has no sales, minimal cash reserves, and a total reliance on external funding to cover basic operating expenses.